ISAR Research Updates

ISAR Research Updates

Research topics prioritised by the ISAR Steering Committee for 2021:

Phenotypic Characteristics, Comorbidities and Response to Therapeutic Interventions Associated with Non-Type 2 Asthma (EMBER)

Aims:

    • To illustrate the baseline prevalence of non-type 2 comorbidities.
    • To describe the baseline demographic and clinical characteristics of these severe asthma patients with non-type 2 comorbidities.

Read More

Effectiveness of Biologics (by classes) in Patients with Different Combination of T2 Biomarkers (IGNITE)

Aims:

    • To describe the prevalence and overlap of elevated T2 biomarkers, related to specific T2 pathways (eosinophils (IL5), FeNO (IL13), IgE (IL4)), and the relationship between the T2 marker profile and the outcome of biological treatment.

Read More

Research Topics:

Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Therapies: a Post Authorization Safety Study (PASS).

Read More

Biologic Patterns, Clinical Outcomes and Health Resource Utilization (CLEAR)

Read More

Impact of Initiating Biologics In Patients on Long Term OCS or Frequent Rescue Steroids (GLITTER)

Read More

Research topics prioritised by the ISAR Steering Committee for 2020:

Define Responders and Non-Responders to Biologics and Describe Their Characteristics Overall and Per Biologic (BEAM)

Aims:

    • To classify responders to biologic treatment by clinical and functional endpoints and describe their characteristics overall and per biologic drug class.
    • To operationally assess response to biologic therapy by clinical and functional endpoints including exacerbations, systemic corticosteroids, asthma control and lung function.
    • To describe and compare baseline (pre-therapy) demographic, clinical and functional characteristics of response and non-response groups to overall biologic treatment and by biologic class.

Read More

Describe the Clinical Outcome Before and After Biologic Treatment by Biologic Class, by Individual Biologic, and by Subgroups of Baseline Characteristics (LUMINANT)

Aims:

    • To describe the proportions of patients by biologic class and drug.
    • To describe clinical outcomes before and after biologic initiation.
    • To describe clinical outcomes before and after biologic initiation for demographic/clinical subgroups (e.g. early/late age of onset, nasal polyps).

Read More

Previously, ISAR Steering Committee (ISC) members voted for 1 fully funded project and 4 academic projects. Henceforth from 2019, the ISC members will vote for 2 fully funded projects.

Research topics prioritised by the ISC members for the year 2019:

Impact of Co-Morbidity in Severe Asthma (PRISM)

Aims:

    • To illustrate the baseline prevalence, demographic and clinical characteristics of severe asthma patients with comorbidities.
    • To investigate the effects of comorbidity (e.g. sleep apnea, nasal polyps) on severe asthma clinical outcomes.

Read More

Comparative effectiveness across severe asthma biologic classes (Anti-IL5 vs Anti lgE) in patients eligible for both modalities (FIRE)

Aims:

    • To describe severe asthma patients eligible for both Anti-IL5 and Anti-IgE.
    • To describe and compare clinical outcomes of patients receiving Anti-IL5 or Anti-IgE versus those maintained on OCS in terms of asthma control, exacerbations, lung function.

Read More

The following research topics were prioritized during the ISC Closed session for 2019 and are open to researchers to join and lead. Submit your interest through our website or contact your country lead for further details.

Research Topics:

What is the OCS landscape: annual consumption, prevalence, outcomes and side-effects of long-term OCS users?Read More
Describe the characteristics of severe asthma patients with inflammatory phenotypes and FEV1 <40%?Read More
What is the characterization of health disparities across countries?Read More
What are the criteria for choosing and switching between similar biological treatment options in patients with atopic and non-atopic severe eosinophilic asthma?Read More

Research topic prioritized by the ISAR steering committee for the second year 2018:

The Characterization and Comparison of Eosinophilic and Non-Eosinophilic Phenotypes of Severe Asthma

Aim:

    • To describe and compare the demographic and clinical features of the eosinophilic versus non-eosinophilic severe asthma phenotypes and to investigate the unique clusters of asthma phenotypes in the ISAR.

Group characterization and feasibility numbers were presented at the REG summit 2019 during the ISAR Research Collaborator Meeting.

Read More

Research Topics:

Hidden Severe Asthma in UK Primary Care*  

Read More

Biologics in Severe Asthma: Utilization Patterns, Causes for Discontinuation and Switching and Adverse Outcomes* (SUNNIE)

Read More

Biomarker Relatability in the International Severe Asthma Registry (BRISAR)

Read More

The Role of Exacerbations on Lung Function Trajectory*

Read More

Identify Predictors (e.g. biomarkers) of Response to Biologics

Read More

Hidden Chronic Asthma within the COPD/ACO Population

Read More

Onset of Asthma in Severe Asthma Patients (PATH)

Read More

Relationship between Socioeconomic Status and Asthma Outcome (RADIANT) 

Read More

 *Funded Studies

Research topic prioritized by the ISAR steering committee for the inaugural year 2017:

Demographic and Clinical Characteristics of Severe Asthma Patients Worldwide

Aim:

    • To describe and compare the demographic and clinical characteristics of the severe asthma population globally

Characteristics described:

    • Demographic Distribution, Medication, Comorbidities, Asthma Control, Eosinophils, and IgE counts, Lung Function, Healthcare Resource Utilization, etc.

4,990 patients from five countries have contributed to this first research project of ISAR.

Read More